Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study
Galen E. Switzer(University of Pittsburgh), Michael A. Pulsipher(Primary Children's Hospital), Brandon Hayes‐Lattin(Oregon Health & Science University), Deidre M. Kiefer(National Marrow Donor Program), Rebecca Drexler(National Marrow Donor Program), RaeAnne M. Besser(National Marrow Donor Program), Hati Kobusingye(National Marrow Donor Program), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust), Michael Linenberger(Fred Hutch Cancer Center), Jessica G. Bruce(University of Pittsburgh), Scott D. Rowley(Johns Hopkins Hospital), Mary M. Horowitz(Medical College of Wisconsin), Mark R. Litzow(Dana-Farber Cancer Institute), Roberta King(University of Iowa), Dennis L. Confer(National Marrow Donor Program), Brian J. Bolwell(Cleveland Clinic), Marcie Riches(Medical College of Wisconsin)
Cited by 13
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
|Blood|2001|701
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
|Journal of Clinical Oncology|2001|682
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664